China Medical System Holdings Limited
0867
株式のランク
#4761
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
株価
$1.30
時価総額
$3.16B
変化（1日）
-2.12%
変化（1年）
-23.42%
国
HK
取引 China Medical System Holdings Limited (0867)
カテゴリー
Healthcare
China Medical System Holdings Limited（0867）のP/E比率
October 2026 時点のP/E比率 TTM 14.33
China Medical System Holdings Limited の最新の財務報告および株価によると、現在の P/E (TTM) は 14.33 です。2023 年末時点での P/E は 12.62 でした。
China Medical System Holdings Limited の P/E 比率の履歴（2006 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 14.33 | 34.83% |
| 2024 | 10.63 | -15.81% |
| 2023 | 12.62 | 54.59% |
| 2022 | 8.16 | -5.85% |
| 2021 | 8.67 | 21.84% |
| 2020 | 7.12 | -43.87% |
| 2019 | 12.68 | 47.67% |
| 2018 | 8.59 | -61.87% |
| 2017 | 22.52 | 13.35% |
| 2016 | 19.87 | -16.07% |
| 2015 | 23.67 | 0.72% |
| 2014 | 23.50 | -6.23% |
| 2013 | 25.06 | 14.26% |
| 2012 | 21.93 | 29.37% |
| 2011 | 16.96 | -48.68% |
| 2010 | 33.04 | -0.72% |
| 2009 | 33.28 | 1,346.58% |
| 2008 | 2.30 | -36.83% |
| 2007 | 3.64 | -49.59% |
| 2006 | 7.22 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 143.92% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。